Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non-Current Deffered Revenue: 2020-2023

Historic Non-Current Deffered Revenue for Candel Therapeutics (CADL) over the last 2 years, with Sep 2023 value amounting to $108,000.

  • Candel Therapeutics' Non-Current Deffered Revenue was N/A to $108,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $108,000, marking a year-over-year change of. This contributed to the annual value of $144,000 for FY2022, which is 83.89% down from last year.
  • Candel Therapeutics' Non-Current Deffered Revenue amounted to $108,000 in Q3 2023, which was down 10.00% from $120,000 recorded in Q2 2023.
  • In the past 5 years, Candel Therapeutics' Non-Current Deffered Revenue ranged from a high of $894,000 in Q4 2021 and a low of $108,000 during Q3 2023.
  • Its 3-year average for Non-Current Deffered Revenue is $361,857, with a median of $144,000 in 2022.
  • In the last 5 years, Candel Therapeutics' Non-Current Deffered Revenue surged by 41.46% in 2021 and then plummeted by 83.89% in 2022.
  • Quarterly analysis of 4 years shows Candel Therapeutics' Non-Current Deffered Revenue stood at $632,000 in 2020, then soared by 41.46% to $894,000 in 2021, then crashed by 83.89% to $144,000 in 2022, then reached $108,000 in 2023.
  • Its last three reported values are $108,000 in Q3 2023, $120,000 for Q2 2023, and $132,000 during Q1 2023.